Osborn Williams & Donohoe LLC Reduces Stake in Eli Lilly and Company (NYSE:LLY)
Osborn Williams & Donohoe LLC cut its position in Eli Lilly and Company (NYSE:LLY) by 6.5% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 5,790 shares of the company’s stock after selling 400 shares during the period. Osborn Williams & Donohoe LLC’s holdings in Eli Lilly and were worth $477,000 at the end of the most recent reporting period.
A number of other large investors have also modified their holdings of LLY. First Command Financial Services Inc. boosted its stake in shares of Eli Lilly and by 7.3% in the first quarter. First Command Financial Services Inc. now owns 1,227 shares of the company’s stock worth $103,000 after buying an additional 84 shares in the last quarter. Heritage Trust Co acquired a new stake in shares of Eli Lilly and during the first quarter worth about $135,000. Point72 Asia Hong Kong Ltd boosted its stake in shares of Eli Lilly and by 237.4% in the first quarter. Point72 Asia Hong Kong Ltd now owns 1,761 shares of the company’s stock worth $148,000 after buying an additional 1,239 shares in the last quarter. Penserra Capital Management LLC boosted its stake in shares of Eli Lilly and by 9.5% in the first quarter. Penserra Capital Management LLC now owns 2,024 shares of the company’s stock worth $170,000 after buying an additional 176 shares in the last quarter. Finally, American National Bank boosted its stake in shares of Eli Lilly and by 5.2% in the second quarter. American National Bank now owns 2,088 shares of the company’s stock worth $172,000 after buying an additional 104 shares in the last quarter. Hedge funds and other institutional investors own 75.59% of the company’s stock.
Shares of Eli Lilly and Company (NYSE:LLY) traded down 0.94% during trading on Friday, hitting $77.07. 4,061,282 shares of the stock were exchanged. The firm’s 50 day moving average price is $82.39 and its 200-day moving average price is $81.90. The stock has a market cap of $81.31 billion, a P/E ratio of 33.35 and a beta of 0.34. Eli Lilly and Company has a 52 week low of $64.18 and a 52 week high of $86.72.
Eli Lilly and (NYSE:LLY) last issued its earnings results on Tuesday, July 25th. The company reported $1.11 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.05 by $0.06. The business had revenue of $5.82 billion for the quarter, compared to analyst estimates of $5.60 billion. Eli Lilly and had a net margin of 11.12% and a return on equity of 28.71%. Eli Lilly and’s revenue was up 7.8% on a year-over-year basis. During the same period in the prior year, the firm earned $0.86 earnings per share. On average, analysts predict that Eli Lilly and Company will post $4.16 EPS for the current year.
The business also recently announced a quarterly dividend, which will be paid on Friday, September 8th. Investors of record on Tuesday, August 15th will be paid a dividend of $0.52 per share. This represents a $2.08 annualized dividend and a yield of 2.70%. The ex-dividend date of this dividend is Friday, August 11th. Eli Lilly and’s dividend payout ratio is presently 90.04%.
TRADEMARK VIOLATION NOTICE: This piece was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The original version of this piece can be viewed at https://www.thecerbatgem.com/2017/08/19/osborn-williams-donohoe-llc-decreases-position-in-eli-lilly-and-company-nyselly-updated.html.
A number of equities research analysts have issued reports on LLY shares. UBS AG cut shares of Eli Lilly and to a “hold” rating and set a $85.00 price target for the company. in a report on Wednesday, July 26th. Argus cut shares of Eli Lilly and from a “buy” rating to a “hold” rating and upped their price target for the company from $64.18 to $81.00 in a report on Thursday, April 27th. They noted that the move was a valuation call. Jefferies Group LLC restated a “buy” rating and set a $93.00 price target on shares of Eli Lilly and in a report on Thursday, June 22nd. Sanford C. Bernstein restated an “outperform” rating and set a $88.00 price target on shares of Eli Lilly and in a report on Sunday, May 21st. Finally, BMO Capital Markets set a $71.00 price target on shares of Eli Lilly and and gave the company a “sell” rating in a report on Tuesday, April 25th. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and twelve have issued a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $88.27.
In other Eli Lilly and news, VP Michael J. Harrington sold 22,833 shares of the firm’s stock in a transaction on Friday, June 9th. The shares were sold at an average price of $79.97, for a total value of $1,825,955.01. Following the transaction, the vice president now directly owns 62,056 shares of the company’s stock, valued at $4,962,618.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Melissa S. Barnes sold 1,900 shares of the firm’s stock in a transaction on Monday, June 12th. The shares were sold at an average price of $80.78, for a total transaction of $153,482.00. Following the completion of the transaction, the insider now directly owns 14,041 shares in the company, valued at $1,134,231.98. The disclosure for this sale can be found here. Over the last three months, insiders have sold 669,733 shares of company stock worth $55,845,287. 0.20% of the stock is owned by insiders.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Stock Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related stocks with our FREE daily email newsletter.